Market Overview - US stock futures remained steady ahead of delayed data releases that are expected to provide insights into the economy, but are unlikely to alter expectations for interest rate cuts [1] - The S&P 500, Nasdaq 100, and Dow Jones Industrial Average futures showed little movement, following three consecutive gains for US stocks at the start of the week [2] - The S&P 500 is approximately 0.3% away from its all-time high, indicating strong market performance despite previous shifts away from AI and tech stocks [3] Economic Data - Recent data, including a surprising drop in inflation and a lukewarm labor market report, have maintained expectations for interest rate cuts in 2026 [4] - Upcoming data releases include the third quarter GDP and December consumer confidence, which are critical for assessing the health of the US economy [4][5] Company News - Novo Nordisk received FDA approval for its weight-loss pill, Wegovy, which is expected to enhance its market position against US competitor Eli Lilly [5][6] - The approval is significant for Novo Nordisk as it aims to recover from a challenging year marked by declining shares and profit warnings due to increased competition [6]

Company and Industry Insights - Novo Nordisk's US-listed stock experienced a significant increase in premarket trading after receiving official US approval to market its Wegovy weight-loss pill [5] - The US economy demonstrated strong resilience with a reported GDP growth of 4.3% annualized rate in Q3, surpassing the expected 3.3%, indicating robust consumer spending [4] - The upcoming consumer confidence data from the Conference Board is anticipated to provide insights into the K-shaped economy affecting American shoppers, which is a key narrative for 2025 [5]